The flag can be used to review using this field more highly prioritise together with the such requests for the retrospective flag. Authoriser and the (Hospital, NBA) Dispenser (Hospital, NBA) Previous Treatment A record of a previously administered course of immunoglobulin treatment. Column Type Description Validation Primary purpose for Secondary purpose for Consequence if not Proposed use and collection collection collected Disclosure Ig The product Valid Values The collection of type of The evaluation of Failure to collect and Use Transparent to Treatment LOV: – Type product types of the product Ig Product that was used previous treatment display the previous some users of system Types previous brand in previous treatments when linked with treatment type may (see security matrix). Immunoglobulin names for may support the clinical response result in patients being No disclosure other treatment. each of : allocation of the correct provides important allocated a different than at level of /best treatment type for intelligence to build the product at next IVIg aggregated current or future evidence base and infusion. Different SCIg reports for clinical treatments. Product potentially assess brands have different NHIg governance and Ig type (rather than brand) performance of infusion rates and may governance purposes. is specific for indication different brands by cause adverse reactions. and condition however; condition. Constraints exist in it is preferable to retain some jurisdictions patients on the same regarding the number
The flag can be used to more highly prioritise such requests for the Authoriser and the Dispenser (Hospital, NBA) review using this field together with the retrospective flag. (Hospital, NBA) Previous Treatment A record of a previously administered course of immunoglobulin treatment. Column Type Description Validation Primary purpose for collection Secondary purpose for collection Consequence if not collected Proposed use and Disclosure Treatment Type LOV: Ig product Types The product types of the previous Immunoglobulin treatment. Valid Values product brand names for each of : IVIg SCIg NHIg The collection of type of Ig Product that was used in previous treatments may support the allocation of the correct /best treatment type for current or future treatments. Product type (rather than brand) is specific for indication and condition however; it is preferable to retain patients on the same The evaluation of previous treatment when linked with clinical response provides important intelligence to build the evidence base and potentially assess performance of different brands by condition. Failure to collect and display the previous treatment type may result in patients being allocated a different product at next infusion. Different brands have different infusion rates and may cause adverse reactions. Constraints exist in some jurisdictions regarding the number Use – Transparent to some users of system (see security matrix). No disclosure other than at level of aggregated reports for clinical governance and Ig governance purposes.